We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.50 | 0.52% | 1,648.00 | 1,648.00 | 1,648.50 | 1,656.00 | 1,644.50 | 1,650.50 | 542,224 | 10:23:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.79 | 67.97B |
From Apr 2019 to Apr 2024
By Colin Kellaher
Thermo Fisher Scientific Inc. (TMO) Thursday said it agreed to buy a drug-substance manufacturing site in Cork, Ireland, from U.K. drug maker GlaxoSmithKline PLC (GSK) for about 90 million euros ($101 million) in cash.
The Waltham, Mass., company said the acquisition expands its development and commercial capabilities for active pharmaceutical ingredients, also known as APIs.
Thermo Fisher said the Cork site, which has more than 400 employees, produces highly specialized APIs for diseases such as childhood cancer, depression and Parkinson's.
Thermo Fisher, which expects to complete the acquisition by the end of the year, said it will continue to produce APIs for Glaxo under a multi-year supply agreement, adding that it will also use the site for other customers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 16, 2019 06:25 ET (10:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
